GIP and type 2 diabetes mellitus: However, the potential for delaying or preventing the progression of T2DM in patients treated with GIP and GLP-1 remains uncertain, as there is currently no definitive evidence from human studies demonstrating that enhanced incretin activity directly affects β-cell mass or alters the progressive loss of insulin secretory capacity in humans.